Search results

Updated results show radiation therapy using lutetium-177 improved survival in advanced prostate cancer.

ANSTO is proud to announce that a license has been issued by the Therapeutic Goods Administration to produce Lutetium-177 (Lu-177) for use in clinical trials.

Scandium 47, a therapeutic radioisotope and potential theranostic, has been produced for the first time at ANSTO. Theranostics are used to both diagnose and treat disease.

Detailed data on ANSTO electricity use and CO2 emissions for FY2024 - FY2025

On the 10th of October 2025, the Minister for Industry, Science and Technology provided his Statement of Expectations to ANSTO.

The celebration of the UN’s International Women’s Day 2023 has a theme that highlights the power of innovative IT to combat discrimination and the marginalisation of women globally.

Paper on redefinition of the kilogram receives international award

ANSTO participates in nuclear medicine congress

ANSTO has signed a strategic agreement with the Australian National University and sets the relationship between the two organisations, who collaborate on important projects, such as the fusion energy project ITER and space research, well into the future.

This instrument can measure reflectivity at air-solid or air-liquid interfaces.

Agreement extends Taiwan’s National Synchrotron Radiation Research Center’s operation of neutron scattering instrument at ANSTO

Ultra small angle neutron scattering on Kookaburra is used to study the size and shape of objects of size 10 micrometres and below.

Environmental scientists at ANSTO have been undertaking research to gain a better understanding of the potential impact of contaminants on decommissioned offshore oil and gas infrastructure since 2017